Login to Your Account

First patient dosed in Advaxis’ phase III cervical cancer trial

By Michael Fitzhugh
Staff Writer

Monday, February 6, 2017

A phase III trial testing the ability of Advaxis Inc.’s lead immunotherapy candidate, axalimogene filolisbac, to improve disease-free survival among patients with high-risk locally advanced cervical cancer has enrolled and dosed its first patient.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription